Actively Recruiting
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Led by Regeneron Pharmaceuticals · Updated on 2026-04-24
54
Participants Needed
5
Research Sites
128 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA). The aim of the study is to see how safe and tolerable the study drug is when used as an injection in the eye. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood and the fluid in the eye at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
CONDITIONS
Official Title
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Study eye with diagnosis of geographic atrophy due to age-related macular degeneration
- Study eye with total geographic atrophy area of about 2.5 mm squared or larger at screening
- Best corrected visual acuity of 60 letters or worse on ETDRS charts (approximately 20/63 vision or worse) in the study eye at screening and baseline visit
You will not qualify if you...
- Geographic atrophy caused by conditions other than dry AMD in either eye
- History or current signs of macular neovascularization or retinal fluid in either eye
- Other eye diseases such as high intraocular pressure above 25 mm Hg, diabetic retinopathy, or eye infections/inflammation
- Previous or current eye injections of any kind within 3 months before screening, except complement inhibitor therapy for GA if last dose was at least 3 months ago
- Any prior systemic treatment for dry AMD except oral supplements or vitamins
- History or current use of systemic complement inhibitor therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Colorado Retina Associates
Lakewood, Colorado, United States, 80228
Actively Recruiting
2
Ophthalmic Consultants of Boston
East Weymouth, Massachusetts, United States, 02189
Actively Recruiting
3
Austin Retina Associates
Austin, Texas, United States, 78705
Actively Recruiting
4
Retina Foundation of the Southwest
Dallas, Texas, United States, 75231
Actively Recruiting
5
Retina Consultants Texas
The Woodlands, Texas, United States, 77384
Actively Recruiting
Research Team
C
Clinical Trials Administrator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here